Absci Q3 net loss widens

Overview

Company reported a net loss of $28.7 mln for Q3 2025

Result Drivers

Research and development expenses were $19.2 million for the three months ended September 30, 2025 compared to $18.0 million for the three months ended September 30, 2024.

Key Details

MetricBeat/MissActualConsensus Estimate
Q3 Net Income-$28.71 mln
Q3 Basic EPS-$0.20
Q3 Operating Expenses$30.53 mln
Q3 Operating Income-$30.15 mln
Q3 Pretax Profit-$28.60 mln
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell" The average consensus recommendation for the biotechnology & medical research peer group is "buy" Wall Street's median 12-month price target for Absci Corp is $8.00, about 56.9% above its November 11 closing price of $3.45 Press Release: ID:nGNX499lTz For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on AbSci

See all news